secwatch.observer — SEC 8-K summary
======================================

Issuer:     ASSEMBLY BIOSCIENCES, INC. (ASMB)
CIK:        0001426800
Form:       8-K
Filed at:   2025-08-08T23:59:59+00:00
Accession:  0001193125-25-176138
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Assembly Bio reports 94% reduction in HSV-2 shedding with ABI-5366 350mg weekly in Phase 1b
--------------------------------------------------------------------------------

- 94% reduction in HSV-2 shedding rate (p<0.01) for 350mg weekly dose vs placebo over 29-day evaluation.
- 98% reduction in high viral load shedding (p<0.05) and 94% reduction in genital lesion rate (p<0.01) with 350mg weekly.
- ABI-5366 well-tolerated; majority of TEAEs Grade 1-2; no serious adverse events reported.
- PK supports weekly and potential monthly dosing; Phase 2 preparation initiated; chronic tox studies complete.
- Gilead has opt-in rights to the helicase-primase program; ABI-1179 and monthly cohort data expected fall 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1426800/000119312525176138/0001193125-25-176138-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1426800/000119312525176138/d802767d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-176138

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer